Patents Assigned to Glycomed, Incorporated
-
Patent number: 5892112Abstract: Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.Type: GrantFiled: January 21, 1994Date of Patent: April 6, 1999Assignees: Glycomed Incorporated, The University of FloridaInventors: Daniel E. Levy, Damian Grobelny, Cho Tang, Kevin R. Holme, Richard E. Galardy, Gregory S. Schultz, Asaad Nematalia, John H. Musser
-
Patent number: 5874411Abstract: Disclosed are novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties, pharmaceutical compositions containing such oligosaccharide glycosides and to methods of using such oligosaccharide glycosides to modulate cell-mediated immune responses in a mammal.Type: GrantFiled: November 13, 1996Date of Patent: February 23, 1999Assignee: Glycomed IncorporatedInventors: Om P. Srivastava, Geeta Srivastava, Roman Szweda, David R. Bundle, Ole Hindsgaul, H. Rizk Hanna, Kevin Holme, Frank W. Barresi, Minghui Du
-
Patent number: 5849709Abstract: Saccharopeptides and methods of using the novel saccharopeptides are described having the following structural formula I:W--?--Y--W--!.sub.m (I)wherein W is independently one or more saccharide(s); Y is independently --CO--NH-- or --NH--CO--; and m is an integer greater than or equal to one; or structural formula II:W--Y--?W--X--W--Y!.sub.n --W (II)wherein W is independently one or more saccharide(s); S is a difunctional or polyfunctional alkyl, aryl or aralkyl group, lipid, amino acid or peptide capable of covalently joining together said saccharides; Y is independently --CO--NH-- or --NH--CO--; and n is an integer greater than or equal to zero; or formula III:W--Y.sup.1 --X.sup.1 --Y.sup.2 --W (III)wherein W is independently one or more saccharide(s); X.sup.1 is a difunctional or polyfunctional alkyl, aryl or aralkyl group capable of covalently joining together said saccharides; Y.sup.1 is --NH--CO--; and Y.sup.2 is --CO--NH--.Type: GrantFiled: May 10, 1995Date of Patent: December 15, 1998Assignee: Glycomed IncorporatedInventors: Peter Fugedi, Csaba Peto
-
Patent number: 5837689Abstract: Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits binding between those groups and the selecting, such compounds being represented by the following general structural formula I: ##STR1##Type: GrantFiled: February 21, 1996Date of Patent: November 17, 1998Assignee: Glycomed IncorporatedInventors: Mark B. Anderson, Daniel E. Levy, Peng Cho Tang, John H. Musser, Narasinga Rao
-
Patent number: 5837690Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.Type: GrantFiled: June 6, 1995Date of Patent: November 17, 1998Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5808021Abstract: Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated upto about 99% and 75% desulfated at the 2-O and 3-O positions, respectively.Type: GrantFiled: April 10, 1997Date of Patent: September 15, 1998Assignee: Glycomed IncorporatedInventors: Kevin R. Holme, Weisheng Liang, David J. Tyrrell, Patrick N. Shaklee
-
Patent number: 5795875Abstract: Compositions and methods of making selectively O-desulfated heparin compositions, preferably 6-O-desulfated heparin compositions, wherein the methods permit regulating the degree of 6-O-desulfation. The compositions are useful for treating various diseases, including cancer, angiogenesis, shock, ischemia reperfusion injury, inflammation, and cardiovascular diseases including restenosis.Type: GrantFiled: January 9, 1997Date of Patent: August 18, 1998Assignee: Glycomed IncorporatedInventors: Kevin R. Holme, Patrick N. Shaklee, Masayuki Ishihara
-
Patent number: 5789385Abstract: Compounds that possess selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs, derivatives, or mimics of these groups, such that sialic acid and fucose or their mimics are separated by a linker that permits binding between those groups and the selecting, such compounds being represented by the following general structural formula I: ##STR1##Type: GrantFiled: February 21, 1996Date of Patent: August 4, 1998Assignee: Glycomed IncorporatedInventors: Mark B. Anderson, Daniel E. Levy, Peng Cho Tang, John H. Musser, Narasinga Rao, Jing Rong Cui
-
Patent number: 5773438Abstract: Synthetic mammalian matrix metalloprotease inhibitors are disclosed that are useful for treating or preventing diseases wherein said diseases are caused by unwanted mammalian matrix metalloprotease activity and include skin disorders, keratoconus, restenosis, rheumatoid arthritis, wounds, cancer, angiogenesis and shock.Type: GrantFiled: June 5, 1994Date of Patent: June 30, 1998Assignees: Glycomed Incorporated, The University of FloridaInventors: Daniel E. Levy, Damian Grobelny, Cho Tang, Kevin R. Holme, Richard E. Galardy, Gregory S. Schultz, Asaad Nematalia, John H. Musser
-
Patent number: 5763582Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.Type: GrantFiled: June 6, 1995Date of Patent: June 9, 1998Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5750508Abstract: Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structure formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.Type: GrantFiled: June 16, 1993Date of Patent: May 12, 1998Assignee: Glycomed IncorporatedInventors: Falguni Dasgupta, John Henry Musser
-
Patent number: 5739115Abstract: A novel class of highly sulfated maltooligosaccharide having heparin-like activity is described, as well as methods for using these oligosaccharides to treat certain diseases including cancer, and retinopathies.Type: GrantFiled: September 26, 1994Date of Patent: April 14, 1998Assignee: Glycomed IncorporatedInventors: Peter Fugedi, David J. Tyrrell, Robert J. Tressler, Robert J. Stack, Masayuki Ishihara
-
Patent number: 5728685Abstract: Compounds and methods of making them having the following formula are described which bind to selectin receptors and thus modulate the course of inflammation, cancer and related diseases by modulating cell-cell adhesion events: ##STR1## wherein each R.sup.1 is independently H or lower alkyl (1-4C); R.sup.2 is H, OH or lower alkyl (1-4C), or a lipophilic group such as a higher alkyl group (5-15C), alkylaryl or one or more additional saccharide residues;R.sup.3 is a negatively charged moiety including SO.sub.4.sup.2-, PO.sub.4.sup.2-, or related group;Y is H or lower alkyl (1-4C); andX is H or --CHR.sup.4 (CHOR.sup.1).sub.2 CHR.sup.5 OR.sup.1 wherein R.sup.4 and R.sup.5 are each independently H, lower alkyl (1-4C), or taken together result in a five- or six-membered ring optionally containing a heteroatom selected from the group consisting of O, S, and NR.sup.1 ;said five- or six-membered ring optionally substituted with one substituent selected from the group consisting of R.sup.1, CH.sub.2 OR.sup.1, OR.sup.Type: GrantFiled: June 6, 1995Date of Patent: March 17, 1998Assignee: Glycomed IncorporatedInventors: Saeed A. Abbas, Falguni Dasgupta, Darwin Asa, John H. Musser, Mina A. Nashed
-
Patent number: 5696100Abstract: Methods of making and using, as prophylactics or therapeutics for preventing or treating certain diseases including cancer, O-desulfated heparin compositions, preferably 2-O, 3-O desulfated heparin compositions, wherein the methods permit regulating the degree of 2-O, 3-O desulfation to produce compositions that are variably desulfated upto about and 75% desulfated at the 2-O and 3-O positions, respectively.Type: GrantFiled: February 6, 1995Date of Patent: December 9, 1997Assignee: Glycomed IncorporatedInventors: Kevin R. Holme, Weisheng Liang, Patrick N. Shaklee
-
Patent number: 5695738Abstract: Compositions of sterodial glycosides are described wherein the glycoside is linked directly, or indirectly to a desired steroidal compound via a carbon, or similar stable linkage, and methods of using the compositions to treat patients by binding to and/or blocking cellular receptors for a variety of diseases including cancer, inflammation, and autoimmune diseases.Type: GrantFiled: June 15, 1995Date of Patent: December 9, 1997Assignee: Glycomed IncorporatedInventors: Mark Anderson, John Henry Musser
-
Patent number: 5688922Abstract: 2-Chloromethyl-3-(tri-O-benzyl-.alpha.-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described.Type: GrantFiled: June 6, 1995Date of Patent: November 18, 1997Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5679644Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.Type: GrantFiled: June 6, 1995Date of Patent: October 21, 1997Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5679321Abstract: Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.Type: GrantFiled: June 6, 1995Date of Patent: October 21, 1997Assignee: Glycomed IncorporatedInventors: Falguni Dasgupta, John Henry Musser
-
Patent number: 5660992Abstract: Compounds that are synthetically inexpensive to make relative to the naturally occurring selectin ligands and that retain selectin binding activity are described that have a three-dimensionally stable configuration for sialic acid and fucose, or analogs or derivatives of these groups, such that sialic acid and fucose are separated by a non-carbohydrate linker that permits binding between those groups and the selectins, such compounds being represented by the following general structural formula I(a): ##STR1## wherein m and n are independently an integer of from 1 to 5, Y and Z are independently a connecting moiety selected from the group consisting of --CH.sub.Type: GrantFiled: June 5, 1995Date of Patent: August 26, 1997Assignee: Glycomed IncorporatedInventors: Falguni Dasgupta, John Henry Musser
-
Patent number: 5658880Abstract: Compounds that exhibit selectin binding activity are described and have the following structural formula: ##STR1## where W is selected from a group including structures a-d below ##STR2## wherein p is an integer of from 0-2, q is an integer of from 0-3, and r is an integer of from 0-5;A is selected from the group consisting of .alpha. and .beta. forms of sialic acid, Kemp's acid, quinic acid, R and S forms of mandelic acid, R and S forms of glyceric acid, R and S forms of lactic acid, propionic and acetic acid, and esters and amides thereof, --SO.sub.3, sulfonate, --PO.sub.3, phosphonate, trifluoromethyl, diazine and triazine;B is selected from a group consisting of .alpha. and .beta. forms of fucose, arabinose and esters and substituted forms thereof wherein one or more of the OH groups is independently substituted with F, N.sub.3, NHAc, NHCOCF.sub.3. The remaining variable are described in the specification.Type: GrantFiled: August 12, 1994Date of Patent: August 19, 1997Assignee: Glycomed IncorporatedInventors: Falguni Dasgupta, John H. Musser, Daniel E. Levy, Peng Cho Tang